| Gene symbol | F | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001803.1 (5619..7521) | dbXrefs | |
| Description | Fusion protein (F) | ||||
| Gene symbol | GH1 | Synonyms | GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B, IGHD2, hGH-N | Type of gene | protein-coding |
| Chromosome | 17 | Map location | 17q23.3 | dbXrefs | |
| Description | growth hormone 1 | ||||
| Gene symbol | LIPF | Synonyms | GL, HGL, HLAL | Type of gene | protein-coding |
| Chromosome | 10 | Map location | 10q23.31 | dbXrefs | |
| Description | lipase F, gastric type | ||||
| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| Gene symbol | UL128 | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_006273.2 | dbXrefs | |
| Description | contains signal peptide; similar to CC chemokines; complexed with envelope glycoproteins H and L; essential in non-fibroblast cells; involved in cell entry | ||||
| Gene symbol | UL130 | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_006273.2 (176984..177628, complement) | dbXrefs | |
| Description | envelope glycoprotein UL130 | ||||
| Gene symbol | UL131A | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_006273.2 (177649..178146, complement) | dbXrefs | |
| Description | envelope protein UL131A | ||||
| GTO ID | GTC3052 |
| Trial ID | NCT05397223 |
| Disease | Respiratory Syncytial Virus Infectious Disease | Seasonal Influenza | Cytomegalovirus | COVID-19 |
| Altered gene | F|gB|gH|gL|UL128|UL130|UL131A|S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1345|mRNA-1647|mRNA-1273|Elasomeran|Spikevax;mRNA-1010|FLUAD |
| Phase | Phase1 |
| Recruitment status | Active, Not Recruiting |
| Title | Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Modified mRNA Vaccines Using a Systems Biology Approach in Healthy Adults |
| Year | 2022 |
| Country | United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-CRID-001 |
| Vector information | |||
|
|||
| Cohort1: mRNA-1345 | |||||||
|
|||||||
| Cohort2: mRNA-1647_Days 1 and 57 | |||||||
|
|||||||
| Cohort3: mRNA-1647_Days 1, 57, and 169 | |||||||
|
|||||||
| Cohort4: mRNA-1273 | |||||||
|
|||||||
| Cohort5: mRNA-1010 | |||||||
|
|||||||
| Cohort6: FLUAD | |||||||
|
|||||||